{"id":28069,"date":"2021-09-23T06:20:13","date_gmt":"2021-09-23T04:20:13","guid":{"rendered":"https:\/\/diarisanitat.cat\/?p=28069"},"modified":"2021-09-23T06:20:13","modified_gmt":"2021-09-23T04:20:13","slug":"la-immunoterapia-sobre-cami-per-tractar-el-cancer-de-pulmo","status":"publish","type":"post","link":"https:\/\/amazing-bassi.82-223-8-23.plesk.page\/index.php\/2021\/09\/23\/la-immunoterapia-sobre-cami-per-tractar-el-cancer-de-pulmo\/","title":{"rendered":"La immunoter\u00e0pia s\u2019obre cam\u00ed per tractar el c\u00e0ncer de pulm\u00f3"},"content":{"rendered":"<p>El Vall d\u2019Hebron Institut d\u2019Oncologia (VHIO), que forma part del Campus Vall d\u2019Hebron, ha presentat al congr\u00e9s de la Societat Europea d\u2019Oncologia M\u00e8dica (ESMO) els resultats l\u2019estudi <em>IMpower010<\/em>, que avancen en l&#8217;\u00fas de la immunoter\u00e0pia per tractar el c\u00e0ncer de pulm\u00f3. La investigaci\u00f3 ha aconseguit demostrar que l\u2019\u00fas d\u2019atezolizumab, un antic\u00f2s monoclonal, millora la superviv\u00e8ncia de malaltia en pacients de c\u00e0ncer de pulm\u00f3 ressecat en estadi II-IIIA, PD-L1 positiu despr\u00e9s de la cirurgia i quimioter\u00e0pia.<\/p>\n<p>\u00ab\u00c9s la primera vegada que un assaig de fase III demostra que l\u2019\u00fas d\u2019immunoter\u00e0pia despr\u00e9s de la quimioter\u00e0pia adjuvant pot oferir una opci\u00f3 de tractament prometedora que estengui la superviv\u00e8ncia lliure de malaltia en pacients amb c\u00e0ncer de pulm\u00f3 no microc\u00edtic ressecat en estadi II-IIIA, particularment en persones amb tumors que expressen PD-L1; aix\u00f2 podria comportar un canvi en la pr\u00e0ctica cl\u00ednica i una millora cl\u00ednicament significativa per a aquests pacients\u00bb, comenta la Dra. Enriqueta Felip, cap del Grup de Tumors Tor\u00e0cics i C\u00e0ncer de Cap i Coll del Vall d\u2019Hebron Institut d\u2019Oncologia (VHIO) i investigadora principal de l\u2019assaig cl\u00ednic.<\/p>\n<p>Els resultats de la investigaci\u00f3, publicats a la revista <em>The Lancet<\/em>, mostren que en el grup de pacients amb tumors que expressen PD-L1 es produ\u00efen recidives del tumor en un 29% dels casos, davant del 44,7% del grup de control. Tamb\u00e9 es va observar que la superviv\u00e8ncia lliure de malaltia millorava. Aquesta superviv\u00e8ncia en aquests pacients despr\u00e9s de dos anys va ser del 74,6% davant del 61% del grup de control. El major benefici amb ateolizumab s\u2019ha observat en el grup de pacients amb tumors que expressen PDL1 en m\u00e9s del 50%.<\/p>\n<p>Segons l&#8217;equip investigador, aquests resultats s\u00f3n rellevants, ja que obren la porta a poder desenvolupar tractaments m\u00e9s efica\u00e7os per a pacients amb aquest tipus de c\u00e0ncer en fases m\u00e9s primerenques..<\/p>\n","protected":false},"excerpt":{"rendered":"<p>El Vall d\u2019Hebron Institut d\u2019Oncologia (VHIO), que forma part del Campus Vall d\u2019Hebron, ha presentat al congr\u00e9s de la Societat Europea d\u2019Oncologia M\u00e8dica (ESMO) els resultats l\u2019estudi IMpower010, que avancen en l&#8217;\u00fas de la immunoter\u00e0pia per tractar el c\u00e0ncer de pulm\u00f3. La investigaci\u00f3 ha aconseguit demostrar que l\u2019\u00fas d\u2019atezolizumab, un antic\u00f2s monoclonal, millora la superviv\u00e8ncia [&hellip;]<\/p>\n","protected":false},"author":6,"featured_media":28070,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[8],"tags":[99,681],"class_list":["post-28069","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-recerca","tag-cancer","tag-cancer-de-pulmo"],"_links":{"self":[{"href":"https:\/\/amazing-bassi.82-223-8-23.plesk.page\/index.php\/wp-json\/wp\/v2\/posts\/28069","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/amazing-bassi.82-223-8-23.plesk.page\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/amazing-bassi.82-223-8-23.plesk.page\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/amazing-bassi.82-223-8-23.plesk.page\/index.php\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/amazing-bassi.82-223-8-23.plesk.page\/index.php\/wp-json\/wp\/v2\/comments?post=28069"}],"version-history":[{"count":0,"href":"https:\/\/amazing-bassi.82-223-8-23.plesk.page\/index.php\/wp-json\/wp\/v2\/posts\/28069\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/amazing-bassi.82-223-8-23.plesk.page\/index.php\/wp-json\/"}],"wp:attachment":[{"href":"https:\/\/amazing-bassi.82-223-8-23.plesk.page\/index.php\/wp-json\/wp\/v2\/media?parent=28069"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/amazing-bassi.82-223-8-23.plesk.page\/index.php\/wp-json\/wp\/v2\/categories?post=28069"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/amazing-bassi.82-223-8-23.plesk.page\/index.php\/wp-json\/wp\/v2\/tags?post=28069"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}